Literature DB >> 10786675

Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors.

J C Darnell1, M L Albert, R B Darnell.   

Abstract

The paraneoplastic neurological disorders provide perhaps the best known example of naturally occurring tumor immunity in humans. For example, patients with paraneoplastic cerebellar degeneration (PCD) appear to suppress the growth of occult breast or ovarian tumors that express a neuronal antigen termed cdr2. PCD patients harbor cdr2-specific CTLs in their peripheral blood, and these cells are likely mediators of the tumor suppression. Whereas cdr2 therefore appears to be the target of an effective immune response in patients with PCD, the general relevance to cancer patients has been unclear, due in part to reports indicating that cdr2 is not expressed in tumors obtained from neurologically normal patients. We have reexamined this question, and we find that cdr2 is widely expressed in such tumors, indicating that cdr2 is in fact an important tumor antigen in the general population of breast and ovarian cancer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10786675

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Paraneoplastic Neurological Syndrome in Fallopian Tube Cancer.

Authors:  E Maas; T Skoberne; A Werner; S Braun; C Jackisch
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-10       Impact factor: 2.915

Review 2.  Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.

Authors:  Ami A Shah; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

3.  IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.

Authors:  Lidia Yshii; Béatrice Pignolet; Emilie Mauré; Mandy Pierau; Monika Brunner-Weinzierl; Oliver Hartley; Jan Bauer; Roland Liblau
Journal:  JCI Insight       Date:  2019-04-04

4.  Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.

Authors:  Madhumita Chatterjee; Laura C Hurley; Nancy K Levin; Matthew Stack; Michael A Tainsky
Journal:  Cancer Biomark       Date:  2017-12-06       Impact factor: 4.388

Review 5.  Paraneoplastic syndromes: an approach to diagnosis and treatment.

Authors:  Lorraine C Pelosof; David E Gerber
Journal:  Mayo Clin Proc       Date:  2010-09       Impact factor: 7.616

6.  T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy.

Authors:  Nathalie E Blachère; Dana E Orange; Emily C Gantman; Bianca D Santomasso; Graeme C Couture; Teresa Ramirez-Montagut; John Fak; Kevin J O'Donovan; Zhong Ru; Salina Parveen; Mayu O Frank; Michael J Moore; Robert B Darnell
Journal:  JCI Insight       Date:  2017-11-02

7.  The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.

Authors:  Kevin J O'Donovan; Jennifer Diedler; Graeme C Couture; John J Fak; Robert B Darnell
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

8.  Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.

Authors:  S E Monstad; A Storstein; A Dørum; A Knudsen; P E Lønning; H B Salvesen; J H Aarseth; C A Vedeler
Journal:  Clin Exp Immunol       Date:  2006-04       Impact factor: 4.330

Review 9.  Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology.

Authors:  V Madan; H Chinoy; C E M Griffiths; R G Cooper
Journal:  Clin Exp Dermatol       Date:  2009-07       Impact factor: 3.470

10.  A T-cell receptor associated with naturally occurring human tumor immunity.

Authors:  Bianca D Santomasso; Wendy K Roberts; Ashby Thomas; Travis Williams; Nathalie E Blachère; Mark E Dudley; Alan N Houghton; Jerome B Posner; Robert B Darnell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.